AIM: To evaluate the effect of different doses of intravitreal triamcinolone acetonide on diffuse diabetic macular oedema. METHODS: The prospective, randomised, double masked, clinical interventional study included 27 eyes (27 patients) with diffuse diabetic macular oedema. They were randomly divided into three study groups receiving an intravitreal injection of filtered triamcinolone acetonide of about 2 mg (n = 8 eyes), 5 mg (n = 10), or 13 mg (n = 9), respectively. Dosage measurement was performed before filtration. Mean follow up was 6.6 (SD 2.4) months (3-12 months). Main outcome measures were visual acuity and intraocular pressure. RESULTS: Maximal increase in visual acuity was significantly (p = 0.046; 95% CI: 0.032 to 2.99; r = 0.38) correlated with the dosage of intravitreal triamcinolone acetonide. Additionally, the duration of the effect of intravitreal triamcinolone acetonide increased significantly with the dosage of intravitreal triamcinolone acetonide (r = 0.45; p = 0.014). Increase in intraocular pressure during follow up was statistically not significantly associated with the dosage used (p = 0.77). CONCLUSIONS: In patients with diffuse diabetic macular oedema receivingintravitreal triamcinolone acetonide, treatment response may last longer and be more pronounced with a dosage of 13 mg than in lower doses of 5 mg or 2 mg. Triamcinolone acetonide induced increase in intraocular pressure may not be markedly associated with the dosage used.
RCT Entities:
AIM: To evaluate the effect of different doses of intravitreal triamcinolone acetonide on diffuse diabetic macular oedema. METHODS: The prospective, randomised, double masked, clinical interventional study included 27 eyes (27 patients) with diffuse diabetic macular oedema. They were randomly divided into three study groups receiving an intravitreal injection of filtered triamcinolone acetonide of about 2 mg (n = 8 eyes), 5 mg (n = 10), or 13 mg (n = 9), respectively. Dosage measurement was performed before filtration. Mean follow up was 6.6 (SD 2.4) months (3-12 months). Main outcome measures were visual acuity and intraocular pressure. RESULTS: Maximal increase in visual acuity was significantly (p = 0.046; 95% CI: 0.032 to 2.99; r = 0.38) correlated with the dosage of intravitreal triamcinolone acetonide. Additionally, the duration of the effect of intravitreal triamcinolone acetonide increased significantly with the dosage of intravitreal triamcinolone acetonide (r = 0.45; p = 0.014). Increase in intraocular pressure during follow up was statistically not significantly associated with the dosage used (p = 0.77). CONCLUSIONS: In patients with diffuse diabetic macular oedema receiving intravitreal triamcinolone acetonide, treatment response may last longer and be more pronounced with a dosage of 13 mg than in lower doses of 5 mg or 2 mg. Triamcinolone acetonide induced increase in intraocular pressure may not be markedly associated with the dosage used.
Authors: Adam Martidis; Jay S Duker; Paul B Greenberg; Adam H Rogers; Carmen A Puliafito; Elias Reichel; Caroline Baumal Journal: Ophthalmology Date: 2002-05 Impact factor: 12.079
Authors: Darius M Moshfeghi; Peter K Kaiser; Ingrid U Scott; Jonathan E Sears; Matthew Benz; Juan P Sinesterra; Richard S Kaiser; Sophie J Bakri; Raj K Maturi; Jonathan Belmont; Paul M Beer; Timothy G Murray; Hugo Quiroz-Mercado; William F Mieler Journal: Am J Ophthalmol Date: 2003-11 Impact factor: 5.258
Authors: Mark L Nelson; Matthew T S Tennant; Arunan Sivalingam; Carl D Regillo; Jonathan B Belmont; Adam Martidis Journal: Retina Date: 2003-10 Impact factor: 4.256
Authors: Dennis S C Lam; Carmen K M Chan; Shaheeda Mohamed; Timothy Y Y Lai; Kenneth K W Li; Patrick S H Li; Chi-Wai Tsang; Wai-Man Chan; Mahesh P Shanmugam Journal: Br J Ophthalmol Date: 2006-09-14 Impact factor: 4.638
Authors: A M Tammewar; L Cheng; O R Kayikcioglu; I A Falkenstein; I Kozak; M H Goldbaum; W R Freeman Journal: Br J Ophthalmol Date: 2008-04-17 Impact factor: 4.638
Authors: M Elizabeth Hartnett; David J Martiniuk; Yuta Saito; Pete Geisen; Lynda J Peterson; Janet R McColm Journal: Invest Ophthalmol Vis Sci Date: 2006-11 Impact factor: 4.799
Authors: David J Browning; Michael M Altaweel; Neil M Bressler; Susan B Bressler; Ingrid U Scott Journal: Am J Ophthalmol Date: 2008-09-05 Impact factor: 5.258
Authors: Giulio Barteselli; Payam Amini; Isaac C Ezon; Joseph T Nezgoda; Lingyun Cheng; William R Freeman Journal: Retina Date: 2015-01 Impact factor: 4.256